Endocannabinoid-System-Ecs Medical Cannabis Studies

• View All (505)

Agonistic Properties of Cannabidiol at 5-HT1a Receptors (2005)

This study demonstrates that cannabidiol (CBD) is a modest agonist at the human 5-HT1a receptor. However, additional work and studies are needed to compare the potential of CBD with other serotonin receptors and other species. The results indicate that CBD is potentially useful beyond the domain of cannabinoid receptors. View study
An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors (2017)

View study
Anandamide and 2-arachidonoylglycerol- pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids (2012)

There is evidence suggesting that AEA and 2-AG possess specific pharmacological properties and that they also participate in different forms of synaptic plasticity and in different behavioral functions, such as learning and memory, reward and addiction, antinociception and anxiety. View study
Biphasic Effects of Cannabinoids on Acetylcholine Release in the Hippocampus: Site and Mechanism of Action (2003)

This research was based on the study of the biphasic effects of cannabinoids on the release of acetylcholine in the hippocampus, site and mechanism of action. The results found in this study could help and provide a theoretical framework for understanding endocannabinoids as modulators of neuronal activity dependent on the state. View study
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors (2006)

This review seeks to verify if cannabidiol is an allosteric modulator in mu and delta opioid receptors. This study showed that cannabidiol is an allosteric modulator in mu and delta opioid receptors. This property is shared by THC but not by rimonabant.10 ?M View study
Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor (2014)

There is convergent anatomical and biochemical evidence that functional CB1 receptors are found in the mitochondria of the brain at low levels. With these data it is possible to conclude that there may be a direct relationship between the CB1 receptor and the mitochondrial functions in the brain and can be detected if certain experimental procedures are applied. View study
Cannabinoid Receptors and Endocannabinoids: Evidence for New Players (2006)

In this research we study the evidence that shows that cannabinoids can modulate synaptic transmission, the cardiovascular system and the immune system through receptors other than CB1 and CB2. View study
Cannabinoid receptors and their ligands (2002)

This research focused on the study of cannabinoid receptors and their ligands. The discovery of the system of cannabinoid and endocannabinoid receptors that form the endocannabinoid system has stimulated the development of selective agonists and antagonists of CB1 and CB2. Reverse agonists. The CB1 / CB2 agonists are already used clinically, as antiemetics or to stimulate the appetite. Possible therapeutic uses of cannabinoid receptor agonists include the treatment of multiple sclerosis / spinal cord injury, pain, inflammatory disorders, glaucoma, bronchial asthma, vasodilation that accompanies advanced cirrhosis and cancer. View study
Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain (2011)

Using brain from rats this research focused on the study of the role of CB2 cannabinoid receptors in the brain, we present evidence of the molecular and functional interaction of the CB2 receptor with CB1 cannabinoid receptors. The data obtained in this study show the mechanism by which CB2 receptors can negatively modulate CB1 receptor function. View study
Cannabinoid system and cyclooxygenases inhibitors (2011)

This research focuses its study on summarizing the existing data on the interactions of the nonsteroidal anti-inflammatory drugs NSAIDS-cannabinoids system. It was concluded that some NSAIDs have additional influences on the cannabinoid system either by inhibiting the hydrolase of fatty acid amides (FAAH) or by inhibiting a possible intracellular endocannabinoid transporter. View study
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors (1999)

This investigation was based on the study in rats to verify the mesen- tial vasodilation induced by cannabinoids through an endothelial site different from the CB1 or CB2 receptors. View study
Cannabis and endocannabinoid modulators: Therapeutic promises and challenges (2005)

This summary focuses on cannabis and endocannabinoid modulators and future therapeutic uses and challenges. The article examines the current understanding of CB1, CB2 and other possible cannabinoid receptors View study
Cannabis, a complex plant: different compounds and different effects on individuals (2012)

In the present article a vision of the biochemical bases of cannabis research is shown by examining the different effects of the two main compounds of the plant and the endocannabinoid system, and the different effects on individuals. View study
Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System (2014)

In this investigation it was discovered that CB2 receptors can form heteromers with CB1 receptors in transfected neuronal cells and in pineal gland of rat brain, nucleus accumbens and pale globe. In general, the data obtained in this research illuminates the mechanism by which CB2 receptors can negatively modulate CB1 receptor function. View study
Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions (2014)

In this study, the bibliographical review available related to the clinical deficiency of endocannabinoids (CECD) was carried out. Research results have confirmed that the underlying endocannabinoid deficiencies play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions. View study
Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions (2004)

The present study demonstrates that migraine, fibromyalgia, and other related conditions have common clinical, biochemical, and pathophysiologic patterns that could be treated with cannabinoid medications. View study
Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes (2016)

In this research a reconsideration of the clinical endocannabinoid deficiency is made. Current research supports the theory of migraine, fibromyalgia, irritable bowel and other treatment-resistant syndromes View study
Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown (2010)

This review focuses on the binding of endocannabinoids to cannabinoid receptors. It is based on experimental and computational studies that have been used to demonstrate the nature of the interaction of endocannabinoids with cannabinoid receptors. View study
Endocannabinoid Signaling Regulates Sleep Stability (2016)

In this study we will show the results of a series of experiments in mice that measure sleep with polysomnography after several systemic pharmacological manipulations of the endocannabinoid system. The results support the hypothesis that endocannabinoid signaling through type 1 cannabinoids (CB1) is necessary for the stability of non-rapid eye movements (NREM), but is not necessary for sleep homeostasis. View study
Endocannabinoid signalling and the deteriorating brain (2015)

This research focused on endocannabinoid signaling and brain deterioration. After the approval of the first cannabinoid-based drug for the symptomatic treatment of multiple sclerosis, we investigated how endocannabinoid signaling (eCB) controls and is affected by normal aging and neuroinflammatory and neurodegenerative disorders. View study
Endocannabinoid System in First Trimester Placenta- Low FAAH and High CB1 Expression Characterize Spontaneous Miscarriage (2009)

Endocannabinoid levels are critical to regulate embryonic development and the window of implantation. Placental tissue represents a target for endocannabinoids, whose activity can regulate the outcome of pregnancy. View study
Endocannabinoids and energy homeostasis: An update (2014)

This article studies how the endocannabinoid tone, in addition to reinforcing the reward circuits and the modulation of food intake and health, controls the metabolism of lipids and glucose in several peripheral organs, particularly the liver and adipose tissue. This study gives a new focus on endocannabinoid control of the neurochemical causes and consequences of the imbalance of energy homeostasis, an approach that could lead to new potential treatments for obesity and related morbidities. View study
Endocannabinoids and the haematological system (2007)

This research aims to review the interactions between cannabinoids and the hematological system. Endocannabinoids can regulate platelet function and possibly lead to thrombogenesis, and influence hematopoiesis. View study
Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol (2007)

These findings suggest that the local activity of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MGL) and cyclooxygenase (COX), which is present to a large extent in the endothelium, limits the vasodilator action of endocannabinoids in the arteries small mesenteric rat. Despite the differential roles that these enzymes make in relaxation to anandamide versus 2-AG, the results indicate that the inhibitors of these enzymes increase the vascular impact of the endocannabinoids. View study

Welcome Back

Create Information

Endocannabinoid-System-Ecs Medical Cannabis Studies